Best Chronic Myeloid Leukemia Podcasts (2025)

1
TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today? 20:37

Play Pause

18h ago20:37

20:37

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including: TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan TROP2 ADCS for patients with EGFR-mutated NSCLC TIGIT-targeting agents: domv…

1
157: genetic testing helped stacy martin survive gastric cancer | prophylactic total gastrectomy 27:10

1h ago27:10

27:10

Stacy Martin says genetic testing saved her life. The testing indicated she had the CDH1 mutation. The mutation gave her an 80 percent chance of getting gastric cancer and a 60 percent chance of breast cancer. She opted for a prophylactic total gastrectomy to remove her stomach and addressed the possibility of breast cancer with a bilateral mastect…

1
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer 22:14

13d ago22:14

22:14

In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including: Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selection The rec…

1
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach 26:01

14d ago26:01

26:01

In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including: Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer Results of the phase II REJOICE-Ovarian01 study in patients with platinum-re…

1
156: Jonathan Gegerson survived head and neck cancer | salivary duct carcinoma | taxol | herceptin 25:10

2d ago25:10

25:10

In 2019, Jonathan Gegerson sought medical attention went he felt a lump on the right side of his neck. After a couple of scans and a biopsy, he was diagnosed with salivary duct carcinoma, a rare form of head and neck cancer. Jonathan survived, but not before enduring 67 sessions of radiation, 12 cycles of chemotherapy (carboplatin, taxol, herceptin…

1
Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care 35:16

19d ago35:16

35:16

In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including: Trials of neoadjuvant immunotherapies demonstrating remarkable response…

1
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management 27:48

22d ago27:48

27:48

In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes …

1
Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer 26:10

1M ago26:10

26:10

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on h…

1
Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer 23:57

1M ago23:57

23:57

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare pro…

1
HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options 37:10

1M ago37:10

37:10

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including: Brief overview of BTC and GEA Approved HER2-directed therapies for BTC and GEA and their mechanisms of acti…

1
155: Luke Mutter survived cholangiocarcinoma | systemic chemotherapy | oxaliplatin | folfirinox | trastuzumab 23:40

1M ago23:40

23:40

It took two chemotherapy regimens, but Luke Mutter survived a rare form of bile duct cancer. A CT scan found a 14cm tumor in his liver. At that time, his care team told him he had cancer, but it could not identify the type of cancer. He was put on a systemic chemotherapy cocktail of folfirinox and oxaplatin, which attempt to kill the tumor. When th…

1
154: Linda Trummer survived mantle cell lymphoma | blastoid variant | doxorubicin | vincristine | cytarabine 20:54

2M ago20:54

20:54

It was a stressful journey, but Linda Trummer survived Stage IV mantle cell lymphoma. In 2015, she went to her primary care physician after discovering a lump on her jaw line. That led to a diagnosis of a slow-moving blood cancer, MALtoma. However, further tests revealed a lump under her left arm and the diagnosis was upgraded to Stage IV mantle ce…

1
153: Ty Cedars survived stage two testicular cancer | BEP | cisplatin | beleomycin | etopicide | neuropathy 23:32

2M ago23:32

23:32

In 2021, one day away from his fortieth birthday, Ty Cedars felt pain in one of his testicles and noticed it was enlarged. He contacted his physician, asking to be seen. The following day, en route to a birthday celebration, Ty received a call from his doctor, requesting that Ty come right away. The Alexandria, Louisiana-based schoolteacher soon un…

1
Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma 22:53

2M ago22:53

22:53

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the …

1
Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients 13:57

3M ago13:57

13:57

Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O’Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including: How patients often present with disease-related symptoms Treatment selection considerations for the first-line and second-line setting How to approach palliative care discussions with pa…

1
Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma 16:48

3M ago16:48

16:48

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently u…

1
152: erin bloodworth exercise oncologist | fitness assessment | individualized exercise program | lymphedema | neuropathy 18:06

2M ago18:06

18:06

A clinical exercise physiologist by trade, Erin Bloodworth sought a career change and became an exercise oncologist. This enabled her to take her expertise and apply it to helping cancer patients, which she does through Northwestern Medicine Living Well. Erin says whether a patient is going through cancer treatment or is post-treatment, she puts th…

1
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions 20:20

3M ago20:20

20:20

In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including: Genomic testing options for assessing risk of recurrence Adjuvant treatment duration and holidays with CDK4/6 inhibitors …

1
151: Stewart Greenfield survived stage IV bladder cancer | cisplatin | gemcidibine | novolumab | immunotherapy 20:27

3M ago20:27

20:27

For Stewart Greenfield, the third time was the charm. After checking pictures of his bladder in 2016, two doctors told him he didn't have long to live; a third doctor told him he had Stage IV metastatic bladder cancer, but insisted he needed to be treated. The cancer had burned a hole in his bladder and attacked lymph nodes from his groin to his ne…

1
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas 29:59

3M ago29:59

29:59

In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including: The clinical implications of using DLL3 as a therapeutic target The impact of emerging DLL3-targeted therapies on evolving treatment paradigms How to incorpor…

1
Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective 24:49

3M ago24:49

24:49

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including: Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules Avail…

1
150: Noelle Gatlin survived Stage II pancreatic cancer | Whipple procedure | pancreatic duodenectomy 22:25

3M ago22:25

22:25

Noelle Gatlin had to endure a lengthy, multi-step process, but she survived Stage II pancreatic cancer. A visit to an emergency department revealed a mass near her pancreas. She was transferred to a hospital, where a second CT scan resulted in her diagnosis. Her care team placed a duodenal stent in Noelle, then a bile duct stent. She next underwent…

1
149: Laurie Adami survived follicular non-Hodgkin Lymphoma | Yescarta CAR-T Therapy | Bexxar | Gazvya 43:23

4M ago43:23

43:23

Laurie Adami seemed to have it all. She was the president of her company, at age 40, she had just had a son and still found time to lead an active lifestyle. However, in 2003, her health took a turn for the worse. She felt a lump in her abdomen, experienced frequent, lengthy sinus infections and chronic fatigue. All this led to a diagnosis of Stage…

1
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025 39:12

4M ago39:12

39:12

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings. Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL ECHO: Rituximab-Bendamustine ±…

1
148: Nicole Scott Is A Kidney Cancer Caregiver | Partial Nephrectomy | Caregiver Burnout | Hernia 16:30

4M ago16:30

16:30

Nicole Scott and her husband, Keith, worked at the same Ohio hospital. When Keith noticed abdominal pain in his left side, he thought it was muscle-related because of the physical nature of his job. The pain radiated to his groin, then what had been random occurrences of the pain became more frequent. Nicole urged Keith to seek urgent care. An emer…

1
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting 35:02

4M ago35:02

35:02

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic brea…

1
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC 18:04

4M ago18:04

18:04

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC: Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs…

1
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors? 22:23

4M ago22:23

22:23

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care. Presenters: Eytan M. Stein, MD Chief, Leukemia Service Director, Program for Drug Development in Leukemia Associate Attending P…

1
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025 21:24

4M ago21:24

21:24

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including: The randomized phase III FLAIR trial The randomized phase III SEQUOIA trial The randomized phase III BRUIN CLL-321 trial Pres…

1
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma 31:19

4M ago31:19

31:19

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including: Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC Overview of the Latest Data for the Combination of …

1
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies 35:36

4M ago35:36

35:36

In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients. This podcast was adapted from a live presentation held in May 202…

1
Experts Discuss CELMoDs in Myeloma 35:51

4M ago35:51

35:51

In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: Mechanistic differences between CELMoDs and IMiDs Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma The clinical implicatio…

1
147: Helinka Carr survived bowel cancer | ileostomy bag | pelvic radiation disease | colonoscopy 20:03

5M ago20:03

20:03

When Helinka Carr experienced limited rectal bleeding, because it was limited, she never thought her problem could rise to the level of cancer. She also thought the bleeding might be diverticulitis, which had been suffered by members of her family. However, at the urging of her doctor, she underwent blood tests and a colonoscopy. The latter reveale…

1
146: Guy Nakoa survived Stage IV breast cancer | mastectomy | ibrance | letrozole | radiation treatment 27:07

5M ago27:07

27:07

Guy Nakoa has survived two diagnoses of Stage IV breast cancer. He initially felt a lump in his breast while showering in 2000. Because it wasn't causing him and because he didn't think could not get a type of cancer associated with women, I went more than a decade before he chose to have the lump checked out. In 2014, he sought medical attention, …

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

6M ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
145: Sheila Romanski twice survived breast cancer | autologous stem cell transplant | lumpectomy | diep flap 25:00

6M ago25:00

25:00

Sheila Romanski is with us today after overcoming two diagnoses of breast cancer and the removal of a tumor in her left shoulder thanks to an autologous stem cell transplant. She tells the @CancerInterviews podcast her initial of Stage 1A breast cancer in 1996 came after her doctor suggested a routine mammogram at age 36 when at the time mammograms…

1
144: Daniel Garza, Anal Cancer Survivor – Laguna Beach, California, USA 23:58

6M ago23:58

23:58

In 2015, Daniel Garza experienced bloating and difficulty completing a bowel movement. A subsequent digital rectal exam revealed a mass on his sphincter, which led to a diagnosis of anal cancer. A surgical procedure got rid of the cancer, but it also resulted in his losing half of his sphincter and the temporary presence of a fistula, a tear which …

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

6M ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies 29:36

7M ago29:36

29:36

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers. Mechanisms of action of ADCs: how ADCs selective…

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer 18:34

7M ago18:34

18:34

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…

1
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies 14:09

7M ago14:09

14:09

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how …

1
143: Rick Upchurch survived chronic myelogenous leukemia | oral chemotherapy | blood cancer | tasigna | nilotinib 20:51

7M ago20:51

20:51

Former NFL star Rick Upchurch seemed to be in good health, but in 2010, he began to experience night sweats, fatigue and aches and pains. He saw his doctor, who ordered blood work. The test results revealed his white blood cell count was very high, and his general practitioner gave him the address of another doctor to see. Rick and his wife were sh…

1
142: Jeff Kallis survived renal cell carcinoma | kidney cancer | right kidney nephrectomy | diverticulosis | ct urogram 20:05

7M ago20:05

20:05

Jeff Kallis survived renal cell carcinoma, a form of kidney cancer. When he experienced pain in his lower flank and saw blood in his urine, he sought medical attention. A CT urogram revealed a stone in his left kidney and a mass in his right kidney. A biopsy confirmed he had clear cell renal cell carcinoma. Jeff underwent a radical nephrectomy on h…

1
141: John Morley survived T2 Muscle Invasive Bladder Cancer | cystectomy | prostatectomy | splenectomy 27:41

8M ago27:41

27:41

What John Morley originally thought was a urinary tract infection turned out to be a diagnosis of bladder cancer. At first, he was told it was a mild form of the disease. Then the diagnosis was upgraded to T2 Muscle Invasive Bladder Cancer, requiring a radical cystectomy meaning he would need to get his bladder removed. His care team next told John…

1
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC 14:42

8M ago14:42

14:42

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including: Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastu…

1
140: Jessica Wharton survived breast cancer | chemotherapy | taxol | super radiation | red devil | ptsd 16:06

8M ago16:06

16:06

When Jessica Whorton discovered lumps on her left breast in 2011, she sought medical attention. The doctors she spoke with said breast cancer was not indicated. She walked around with the lumps for another nine months before seeking a second opinion. Tests revealed she had Stage 3A invasive ductal carcinoma. Doctors urged that she get a double mast…

1
139: Susan Svoboda survived hormone positive breast cancer | estrogen inhibitor | invasive ductal carcinoma | lumpectomy 19:46

8M ago19:46

19:46

Susan Svoboda was accustomed to going in for her mammogram every November. She enjoyed a healthy lifestyle, which included running 65 half marathons. But in late 2021, after her mammogram, she was called to return to the doctor's office. After scans and a biopsy, she was diagnosed with Stage 1-2 invasive ductal carcinoma. Given her healthy routine,…

1
138: Albertina Dancy survived liver cancer | fatty liver disease | radiation treatment | chemotherapy 20:08

8M ago20:08

20:08

In 2021, Albertina Dancy began to experience abdominal pain, but that wasn't all. She also had gastrointestinal issues, jaundice and other problems. However, she didn't take them seriously and thought they could be successfully addressed with over-the-counter remedies. When that didn't happen, she sought medical attention. Albertina's doctor said t…

1
137: Karen Humphries twice survived cholangiocarcinoma | bile duct cancer | liver resection | xeloda | chemotherapy 19:51

9M ago19:51

19:51

After a long list of health issues, Karen Humphries was diagnosed with a rare type of bile duct cancer called cholangiocarcinoma. She was initially diagnosed in 2021 with Stage 2B gallbladder cancer, had her gallbladder removed, after which the diagnosis was changed to Stage 4 cholangiocarcinoma. Karen underwent a two-part liver resection and a che…

1
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer 45:08

9M ago45:08

45:08

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical p…